Shares of Sorrento Therapeutics (NASDAQ: SRNE) were up 4.7% as of 10:33 a.m. EDT on Wednesday after rising as much as 14.9% earlier in the day. Why did the stock bounce back after plunging earlier this week? Sorrento didnt reportany news that would provide a catalyst. Instead, it appears that some investors viewed the sell-off as overdone.
The kind of volatility seen with Sorrento isn't unusual for a clinical-stage biotech stock. That's especially true for biotechs developing experimental COVID-19 therapies and vaccines, an area that's moving at a blazingly fast pace.
Sorrento's decline earlier this week stemmed from a couple of stories in the fight against COVID-19. The U.S. Food and Drug Administration (FDA) gave emergency use authorization (EUA) to convalescent plasma in treating COVID-19 on Sunday. The Financial Times also reported on Sunday that the COVID-19 vaccine candidate being developed by AstraZeneca and the University of Oxford could be fast-tracked for EUA by the Trump administration.
The EUA for convalescent plasma could have a greater impact on Sorrento. It's possible that the antibody therapies the biotech is developing could have a harder time gaining market share (assuming approval) if convalescent plasma proves to be effective in treating COVID-19. However, some investors appeared to realize today that all of this is only conjecture.
Sorrento doesn't have any coronavirus-related products on the market yet. That could change in the not-too-distant future, though. The company hopes to soon receive EUA for its COVI-TRACK antibody test. It also expects to file for an EUA for its COVI-TRACE diagnostic test.
10 stocks we like better than Sorrento Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Sorrento Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of August 1, 2020
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.